EOFlow Makes a Significan...
▶ Funding up to 18 billion KRW secured through loans from the Korea Development Bank ▶ Automation to reduce production costs and expand manufacturing capacity EOFlow (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announced that it will make a large i...
Sep.06.2021
EOFlow Officially Launche...
▶ World’s first smartphone app for controlling wearable insulin pump ▶ Improved ease of use by replacing a portable device with a smartphone app ▶ EOPatch Online Education Center is now open to educate and promote benefits of wireless insulin management system EOFlow Co., Ltd. (KOSDAQ: 294090...
Aug.30.2021
EOFlow Signs Mutual Equit...
▶ EOFlow and UXN sign mutual equity investment agreement to strengthen mutual trust for future competitiveness ▶ Convergence of low-power electroosmotic pump with continuous blood glucose measurement technology for the development of two-part and integrated wearable artificial pancreas systems EOFl...
Aug.02.2021
[Medical Observer] New In...
Reporter Park from Medical Observer introduced EOFlow's wearable, disposable insulin pump EOPatch in the article today. (In Korean only: http://www.monews.co.kr/news/articleView.html?idxno=305824) At the bottom of the article, reporter Park introduced EOFlow as a company that suc...
Jul.30.2021
[Medical Observer] EOFlow...
Medical Observer released a CEO interview article today (In Korean only: http://www.monews.co.kr/news/articleView.html?idxno=305828) During the interview, EOFlow's founding CEO Jesse Kim focused on the wearable insulin pump "EOPatch" and its future product portfolio. The rep...
Jul.30.2021
[SK Securities] Sales exp...
SK Securities published a company analysis report on EOFlow today on 22/07/2021. Analyst Lee commented that EOFlow's wearable disposable insulin pump was sold in Korea from 1Q21 and with national healthcare insurance, sales in EOFlow is expected to increase greatly. He also commented t...
Jul.22.2021
[MoneyToday] CEO intervie...
MoneyToday released a CEO interview article on the newspaper and online yesterday (In Korean only: https://news.mt.co.kr/mtview.php?no=2021072014373786320, https://news.mt.co.kr/mtview.php?no=2021072014461679862) Reporter Kim focused on EOFlow's newly established pharmaceutical subsid...
Jul.20.2021
[Hankyung BIO Insight] EO...
EOFlow's establisiment of a wearable pharmaceutical subsidiary 'Pharmeo' to expand on its wearable drug delivery business was introduced on Hankyung BIO Insight on 07/12/2021 (in Korean only): https://www.hankyung.com/it/article/2021071123361 In summary, reporter Ju-Hyun Lee f...
Jul.12.2021
EOFlow establishes a wear...
▶ Leveraging the advantages of EOFlow’s smart wearable drug delivery platform to establish a unique drug-device combination pharma business ▶ ‘Wearable Pharma’: Going beyond insulin for smart wearable disease management EOFlow (KOSDAQ: 294090) (EOFlow or the Company), a prov...
Jul.09.2021
[Financial News] EOFlow p...
Financial News released a CEO interview article today on page 30 of the Financial Newspaper, and online yesterday (In Korean only: https://www.fnnews.com/news/202107011340009046). "EOFlow will start launching in Europe this fall. We're preparing to make entrance into the U.S. market,&...
Jul.02.2021
